| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
127,470,000 |
| Market
Cap: |
1.66(B) |
| Last
Volume: |
878,666 |
Avg
Vol: |
1,074,261 |
| 52
Week Range: |
$11.665 - $20.73 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile NeoGenomics operate a network of cancer-focused testing laboratories in the U.S., Europe and Asia. Co.'s testing services include the following: Cytogenetics (karyotype analysis), a study of chromosomes and their relationship to disease; Fluorescence In-Situ Hybridization, a molecular cytogenetic technique that focuses on detecting and localizing the presence or absence of specific DNA sequences and genes on chromosomes; Flow cytometry, a technique utilized to measure the characteristics of cell populations; Immunohistochemistry and Digital Imaging; Molecular testing; and Morphologic analysis, a process of analyzing cells under the microscope.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
1,049 |
9,748 |
12,417 |
12,417 |
| Total Sell Value |
$16,511 |
$152,803 |
$201,886 |
$201,886 |
| Total People Sold |
1 |
2 |
2 |
2 |
| Total Sell Transactions |
1 |
3 |
4 |
4 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Johnson Kevin C |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,081 |
34,064 |
|
- |
|
| Shovlin Robert J. |
President, Clinical Services |
• – – |
2021-05-25 |
4 |
S |
$39.31 |
$5,134,043 |
D/D |
(130,604) |
150,101 |
|
-24% |
|
| Shovlin Robert J. |
President, Clinical Services |
• – – |
2021-05-25 |
4 |
OE |
$8.03 |
$1,498,530 |
D/D |
126,958 |
280,705 |
|
- |
|
| Weiss Lawrence Martin |
Chief Medical Officer |
• – – |
2021-04-22 |
4 |
OE |
$9.22 |
$503,646 |
D/D |
25,050 |
130,847 |
|
- |
|
| Mallon Mark |
Chief Executive Officer |
• • – |
2021-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
55,736 |
55,736 |
|
- |
|
| Brown Douglas Matthew |
Chief Strategy Officer |
• – – |
2021-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
4,655 |
111,644 |
|
- |
|
| Pedulla Denise E |
General Counsel |
• – – |
2021-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
4,345 |
60,643 |
|
- |
|
| Pedulla Denise E |
General Counsel |
• – – |
2021-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(216) |
56,298 |
|
- |
|
| Cardoza George |
President, Pharma Services |
• – – |
2021-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
6,207 |
377,109 |
|
- |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2021-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
56,423 |
2,474,716 |
|
- |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2021-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,158) |
2,418,293 |
|
- |
|
| Balliet Jennifer |
VP and Chief Culture Officer |
• – – |
2021-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,862 |
26,457 |
|
- |
|
| Balliet Jennifer |
VP and Chief Culture Officer |
• – – |
2021-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(173) |
24,595 |
|
- |
|
| Weiss Lawrence Martin |
Chief Medical Officer |
• – – |
2021-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,276 |
105,797 |
|
- |
|
| Bonello William |
President, Informatics |
• – – |
2021-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
4,345 |
15,473 |
|
- |
|
| Bonello William |
President, Informatics |
• – – |
2021-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(432) |
11,128 |
|
- |
|
| Shovlin Robert J. |
President, Clinical Services |
• – – |
2021-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
6,827 |
153,747 |
|
- |
|
| Shovlin Robert J. |
President, Clinical Services |
• – – |
2021-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(608) |
146,920 |
|
- |
|
| Dieter Cynthia J |
Chief Accounting Officer |
• – – |
2021-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,241 |
1,846 |
|
- |
|
| Mckenzie Kathryn B |
Chief Financial Officer |
• – – |
2021-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
6,207 |
13,535 |
|
- |
|
| Mckenzie Kathryn B |
Chief Financial Officer |
• – – |
2021-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(432) |
7,328 |
|
- |
|
| Pedulla Denise E |
General Counsel |
• – – |
2021-03-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(212) |
56,514 |
|
- |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2021-03-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,339) |
2,420,451 |
|
- |
|
| Balliet Jennifer |
VP and Chief Culture Officer |
• – – |
2021-03-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(212) |
24,768 |
|
- |
|
| Bonello William |
President, Informatics |
• – – |
2021-03-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(500) |
11,560 |
|
- |
|
544 Records found
|
|
Page 5 of 22 |
|
|
0.12 (0.91%) 
